Pitavastatin (antifibrotic in JAK2V617F MF)

Current understanding

To be populated as evidence accumulates.

2026-09-01 — Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.: Preclinical (HTS + Jak2V617F mouse model): monocyte-derived fibrocytes identified as dominant collagen-producing population in JAK2V617F MF; pitavastatin inhibited fibrocyte proliferation in vitro, reduced BM fibrocytes, TGF-β1, and myofibroblasts, reversed marrow fibrosis, and improved anemia in vivo, with patient PB fibrocytes also sensitive. (novelty: 4)